Condition (MeSH)
Ancylostomiasis
ClinicalTrials.gov lists 41 trials for Ancylostomiasis or a narrower condition beneath it. Centers for Disease Control and Prevention has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
41 of the 41 trials are tagged with Ancylostomiasis itself; the rest are tagged with a narrower condition beneath it.
When did Ancylostomiasis trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 4 |
| 2016 | 2 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 41 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ancylostomiasis trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 11 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 6 |
| Phase 4 | 3 |
| Not applicable | 13 |
| Observational | 2 |
How many Ancylostomiasis trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Completed | 33 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ancylostomiasis trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Centers for Disease Control and Prevention | 1 |
Which drugs are being tested for Ancylostomiasis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Albendazole | 10 |
| Mebendazole | 5 |
| Ivermectin | 4 |
| Emodepside | 4 |
| Moxidectin | 3 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Na-APR-1 (M74)/Alhydrogel | 4 |
| Na-GST-1/Alhydrogel | 3 |
| hepatitis B vaccines | 2 |
| 100 μg Na-GST-1/Alhydrogel | 2 |
| Na-ASP-2 Skin Test Reagent | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Ancylostomiasis trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Delusional Episode | 1 | 1 |
| Inguinal hernia | 1 | 1 |
Which publications cover Ancylostomiasis? (4)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. | PLoS neglected tropical diseases | 2011 | Yes |
| Evidence for larval hypobiosis in Australian strains of Ancylostoma duodenale. | Transactions of the Royal Society of Tropical Medicine and Hygiene | 1995 | Yes |
| Hookworm infection. | Scientific American | 1995 | Yes |
| The immunoepidemiology of human hookworm infection. | Parasite immunology | 2004 | No |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Ankylostomiasis | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Ankylostomiasis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Ankylostomiasis | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Ankylostomiasis | 78 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Ankylostomiasis | 78 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.